BLASUBCUTANEOUSVIAL
Approved
Sep 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
25
Data completeness
5/8 — Partial
ARANESP (darbepoetin alfa) by Amgen. Approved for erythropoiesis-stimulating agent [epc]. First approved in 2001.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARANESP (darbepoetin alfa) is a long-acting erythropoiesis-stimulating agent that mimics endogenous erythropoietin to stimulate red blood cell production. It is administered subcutaneously to treat anemia in patients with chronic kidney disease and cancer patients receiving chemotherapy. The drug works by binding to erythropoietin receptors on bone marrow progenitor cells, promoting RBC maturation and hemoglobin synthesis.
$60MPart D
LOE ApproachingDeclining
With lifecycle in LOE-approaching phase and modest Part D spending ($60M), the brand team is likely consolidating and focusing on retention in core patient populations.
Mechanism of Action
Pharmacologic Class:
Erythropoiesis-stimulating Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (25)
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
Started Sep 2021
43 enrolled
Chronic Kidney Disease
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Started Mar 2021
13 enrolled
Myelodysplastic Syndromes
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Started Aug 2019
214 enrolled
AnemiaChronic Kidney Disease Requiring Chronic Dialysis
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
Started Jan 2019
172 enrolled
Anemia of Chronic Kidney Disease
The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers
Started Mar 2017
57 enrolled
Healthy
Worked on ARANESP at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.